Population
Human rhinovirus 14 and its mutants resistant to WIN 52035-2
Design
Preclinical
Authors
Loading...
No immediate clinical use for WIN 52035-2; leaves open targeted antiviral development pending human validation.
WIN 52035-2 inhibits human rhinovirus 14 by blocking attachment and uncoating, with resistance occurring via exclusion or compensation mutations.
Shepard et al. (1993) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: